80 related articles for article (PubMed ID: 25200207)
1. Filamin A interacting protein 1-like as a therapeutic target in cancer.
Kwon M; Libutti SK
Expert Opin Ther Targets; 2014 Dec; 18(12):1435-47. PubMed ID: 25200207
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
[TBL] [Abstract][Full Text] [Related]
3. Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis.
Kwon M; Lee SJ; Wang Y; Rybak Y; Luna A; Reddy S; Adem A; Beaty BT; Condeelis JS; Libutti SK
Int J Cancer; 2014 Jul; 135(1):48-60. PubMed ID: 24327474
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of Filamin A interacting protein 1-like Is associated with promoter methylation and an invasive phenotype in breast, colon, lung and pancreatic cancers [corrected].
Kwon M; Lee SJ; Reddy S; Rybak Y; Adem A; Libutti SK
PLoS One; 2013; 8(12):e82620. PubMed ID: 24340050
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.
Burton ER; Gaffar A; Lee SJ; Adeshuko F; Whitney KD; Chung JY; Hewitt SM; Huang GS; Goldberg GL; Libutti SK; Kwon M
Mol Cancer Res; 2011 Aug; 9(8):1126-38. PubMed ID: 21693594
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Wnt/β-catenin signaling pathway in human cancers.
Yao H; Ashihara E; Maekawa T
Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
[TBL] [Abstract][Full Text] [Related]
7. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
Ramachandran I; Thavathiru E; Ramalingam S; Natarajan G; Mills WK; Benbrook DM; Zuna R; Lightfoot S; Reis A; Anant S; Queimado L
Oncogene; 2012 May; 31(22):2725-37. PubMed ID: 22002305
[TBL] [Abstract][Full Text] [Related]
8. Wnt signaling and cancer development: therapeutic implication.
Paul S; Dey A
Neoplasma; 2008; 55(3):165-76. PubMed ID: 18348648
[TBL] [Abstract][Full Text] [Related]
9. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics.
Takemaru KI; Ohmitsu M; Li FQ
Handb Exp Pharmacol; 2008; (186):261-84. PubMed ID: 18491056
[TBL] [Abstract][Full Text] [Related]
10. Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis.
Kwon M; Rubio G; Wang H; Riedlinger G; Adem A; Zhong H; Slegowski D; Post-Zwicker L; Chidananda A; Schrump DS; Pine SR; Libutti SK
Cancer Res Commun; 2022 Oct; 2(10):1197-1213. PubMed ID: 36860703
[TBL] [Abstract][Full Text] [Related]
11. DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines.
Jingushi K; Takahashi-Yanaga F; Yoshihara T; Shiraishi F; Watanabe Y; Hirata M; Morimoto S; Sasaguri T
Biochem Pharmacol; 2012 Jan; 83(1):47-56. PubMed ID: 22005519
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
Lu H; Hallstrom TC
PLoS One; 2012; 7(8):e42921. PubMed ID: 22900064
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.
Kwon M; Hanna E; Lorang D; He M; Quick JS; Adem A; Stevenson C; Chung JY; Hewitt SM; Zudaire E; Esposito D; Cuttitta F; Libutti SK
Cancer Res; 2008 Sep; 68(18):7332-41. PubMed ID: 18794120
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
[TBL] [Abstract][Full Text] [Related]
15. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.
González-Sancho JM; Aguilera O; García JM; Pendás-Franco N; Peña C; Cal S; García de Herreros A; Bonilla F; Muñoz A
Oncogene; 2005 Feb; 24(6):1098-103. PubMed ID: 15592505
[TBL] [Abstract][Full Text] [Related]
16. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.
Sun J; Zhang D; Bae DH; Sahni S; Jansson P; Zheng Y; Zhao Q; Yue F; Zheng M; Kovacevic Z; Richardson DR
Carcinogenesis; 2013 Sep; 34(9):1943-54. PubMed ID: 23671130
[TBL] [Abstract][Full Text] [Related]
17. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Tsai JH; Hsu LS; Lin CL; Hong HM; Pan MH; Way TD; Chen WJ
Toxicol Appl Pharmacol; 2013 Nov; 272(3):746-56. PubMed ID: 23921149
[TBL] [Abstract][Full Text] [Related]
18. Omega-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-catenin signaling.
Song KS; Jing K; Kim JS; Yun EJ; Shin S; Seo KS; Park JH; Heo JY; Kang JX; Suh KS; Wu T; Park JI; Kweon GR; Yoon WH; Hwang BD; Lim K
Pancreatology; 2011; 11(6):574-84. PubMed ID: 22213040
[TBL] [Abstract][Full Text] [Related]
19. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells.
Kang YJ; Park HJ; Chung HJ; Min HY; Park EJ; Lee MA; Shin Y; Lee SK
Mol Pharmacol; 2012 Aug; 82(2):168-77. PubMed ID: 22550094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
